We have previously modeled biallelic CEBPA mutant AML in the mouse and observed that the combination of N- and C-terminal C/EBPα mutation is optimal for leukemogenesis (Bereshchenko et al., 2009), consistent with the clinically observed mutation pattern. This evidence concerns the gene CEBPA and acute myeloid leukemia.